Skip to search formSkip to main contentSkip to account menu

2,6-dihydroxy-3-cyanopyridine

Known as: 2,6-CNDP, 3-cyano-2,6-dihydroxypyridine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
BOF-A2 (emitefur: 3-(3-[6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl]benzoyl)-1-ethoxy- methyl-5- fluorouracil), a novel 5-FU (5… 
1994
1994
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5… 
1994
1994
Inhibition of Catabolic Pathway of 5‐Fluorouracil by 3‐Cyano‐2,6‐dihydroxypyridine in Human Lung Cancer Tissues
Our studies of the degradation and the phosphorylation of S–fluorouracil (5–FU) in normal and tumor lung tissues from 10 cases of… 
1993
1993
3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
3-Cyano-2,6-dihydroxypyridine (CNDP) was identified as a potent inhibitor (IC50 value, 4.4 nM) of dihydrouracil dehydrogenase… 
1993
1993
Comparative Studies on the Metabolism of New Fluorinated Pyrimidine Drugs in the Liver by in vivo19F Magnetic Resonance Spectroscopic Observation
1‐Ethoxymethyl‐5‐fluorouracil (EM‐FU) is a fluorinated pyrimidine derived from 5‐FU, and 3‐cyano‐2,6‐dihydroxypyridine (CNDP) is… 
1990
1990
[Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
A new 5-fluorouracil (5-FU) derivative, BOF-A2 (3-[3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1- ethoxymethyl- 5… 
1989
1989
Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats
The correlations of the 5‐fluorouracil (5‐FU) level in the plasma and the duration of continuous 5‐FU infusion with the antitumor… 
1989
1989
Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil
Methods for pharmacokinetic modulation of the plasma 5‐fluorouracil (5‐FU) level to increase antitumor activity during continuous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)